» Articles » PMID: 39403607

Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2024 Oct 15
PMID 39403607
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a diverse disease entity and a leading cause of cancer-related mortality worldwide. CRC results from the accumulation of multiple genetic and epigenetic alterations. This heterogeneity of CRC underscores the significance of understanding its molecular landscape, as variations in tumor genetics can greatly influence both patient prognosis and therapeutic response. The molecular complexity of CRC is defined by three major carcinogenesis pathways: chromosomal instability (CIN), microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP). These pathways contribute to the onset and progression of CRC through mutations, epigenetic modifications, and dysregulated cellular signalling networks. The heterogeneous nature of CRC continues to pose challenges in identifying universally effective treatments, highlighting the need for personalized approaches. Hence, the present review aims at unravelling the molecular complexity of CRC that is essential for improving diagnosis, prognostication, and treatment. We detail on the current understanding of the molecular framework of CRC, central signalling pathways of CRC associated with its initiation to a malignant phenotype, further invasion, progression, metastases, and response to therapy. Continued research into CRC's pathways and biomarkers will pave the way for the development of more precise and effective therapeutic strategies, ultimately improving patient outcomes.

Citing Articles

Advances in Molecular Mechanisms and Therapeutic Strategies in Colorectal Cancer: A New Era of Precision Medicine.

Delle Cave D Int J Mol Sci. 2025; 26(1.

PMID: 39796202 PMC: 11719900. DOI: 10.3390/ijms26010346.


Response to Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies [Letter].

Agussalim Cancer Manag Res. 2024; 16:1523-1524.

PMID: 39474511 PMC: 11520707. DOI: 10.2147/CMAR.S500966.

References
1.
Qi J, Zhu Y, Luo J, Tao W . Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 2006; 12(44):7113-7. PMC: 4087771. DOI: 10.3748/wjg.v12.i44.7113. View

2.
Bennett R, Licht J . Targeting Epigenetics in Cancer. Annu Rev Pharmacol Toxicol. 2017; 58:187-207. PMC: 5800772. DOI: 10.1146/annurev-pharmtox-010716-105106. View

3.
Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S . Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. Br J Cancer. 2010; 102(8):1300-5. PMC: 2856015. DOI: 10.1038/sj.bjc.6605644. View

4.
Potapova T, Gorbsky G . The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis. Biology (Basel). 2017; 6(1). PMC: 5372005. DOI: 10.3390/biology6010012. View

5.
Arrington A, Heinrich E, Lee W, Duldulao M, Patel S, Sanchez J . Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012; 13(10):12153-68. PMC: 3497263. DOI: 10.3390/ijms131012153. View